In a USC Keck School of Medicine press release, senior author Susanne Hempel, PhD, said, "The main message is, if your doctor puts you on Paxlovid, you don't have to worry about serious side effects.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is set to bolster and widen ...

Credit: testing/Shutterstock. Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is ...

arthritis drug Actemra. Biogen (NASDAQ:BIIB), which obtained regulatory and commercial rights to Tofidence from the Chinese biotech Bio-Thera Solutions in 2021, launched the monoclonal antibody ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today revealed that Marketing Maven is No. 124 on its fifth annual Inc. Regionals: Pacific ...

Roche’s Actemra may help fight pandemic after all with phase 3 trial results showing it cut the chances of COVID-19 patients, mainly from higher risk minority ethnic backgrounds with pneumonia ...